Anlotinib Plus Immune Checkpoint Inhibitors versus Chemotherapy in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer: A Real World, Exploratory Study.

Drug Des Devel Ther · 2026 · PMC13222604 · PMID 42226757

Europe PMC DOI

hedged sentence

0.0450

closest p · 0.9× alpha

0.0450

boldest claim

The sentences

showed a trendP =0.045actually significant

And the 12-month DoR rate in OG and CG was 50.0% (95% CI: 27.1–69.2%) and 22.2% (95% CI: 3.4–51.3%), which showed a trend toward marginal statistical significance ( χ 2 =4.034, P =0.045).

also in 26,766 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.